DERM
Journey Medical Corp
NASDAQ · Pharmaceuticals
$8.35
+0.00 (+0.00%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 108.31M | 106.46M | 91.38M |
| Net Income | 14.96M | 19.04M | 15.46M |
| EPS | — | — | — |
| Profit Margin | 13.8% | 17.9% | 16.9% |
| Rev Growth | +14.5% | +23.5% | +18.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 88.21M | 81.05M | 98.09M |
| Total Equity | 123.02M | 109.66M | 130.87M |
| D/E Ratio | 0.72 | 0.74 | 0.75 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 21.55M | 19.03M | 16.26M |
| Free Cash Flow | 11.63M | 11.82M | 11.85M |